Tarun Mehra, Dominik Menges, Benedict Gosztonyi, Nicola Miglino, Alexander Ring, Laura Amanda Boos, Bettina Sobottka, Rudolf Aebersold, Melike Ak, Faisal S. Al-Quaddoomi, Silvana I. Albert, Jonas Albinus, Ilaria Alborelli, Sonali Andani, Per-Olof Attinger, Marina Bacac, Monica-Andreea Baciu-Drăgan, Daniel Baumhoer, Beatrice Beck-Schimmer, Niko Beerenwinkel, Christian Beisel, Lara Bernasconi, Anne Bertolini, Bernd Bodenmiller, Ximena Bonilla, Lars Bosshard, Byron Calgua, Ruben Casanova, Stéphane Chevrier, Natalia Chicherova, Ricardo Coelho, Maya D’Costa, Esther Danenberg, Natalie R. Davidson, Reinhard Dummer, Stefanie Engler, Martin Erkens, Katja Eschbach, Cinzia Esposito, André Fedier, Pedro F. Ferreira, Joanna Ficek-Pascual, Anja L. Frei, Bruno Frey, Sandra Goetze, Linda Grob, Gabriele Gut, Detlef Günther, Pirmin Haeuptle, Viola Heinzelmann-Schwarz, Sylvia Herter, Rene Holtackers, Tamara Huesser, Alexander Immer, Anja Irmisch, Francis Jacob, Andrea Jacobs, Tim M. Jaeger, Alva R. James, Philip M. Jermann, André Kahles, Abdullah Kahraman, Viktor H. Koelzer, Werner Kuebler, Jack Kuipers, Christian P. Kunze, Christian Kurzeder, Kjong-Van Lehmann, Mitchell Levesque, Ulrike Lischetti, Flavio C. Lombardo, Sebastian Lugert, Gerd Maass, Markus G. Manz, Philipp Markolin, Martin Mehnert, Julien Mena, Julian M. Metzler, Nicola Miglino, Emanuela S. Milani, Holger Moch, Simone Muenst, Riccardo Murri, Charlotte KY Ng, Stefan Nicolet, Marta Nowak, Monica Nunez Lopéz, Patrick GA Pedrioli, Lucas Pelkmans, Salvatore Piscuoglio, Michael Prummer, Laurie Prélot, Natalie Rimmer, Mathilde Ritter, Christian Rommel, María L. Rosano-González, Gunnar Rätsch, Natascha Santacroce, Jacobo Sarabia del Castillo, Ramona Schlenker
While advances in the understanding of tumor biology through multi-omics profiling hold the promise of substantially improving patient outcomes, the cost implications of such strategies remain unclear. We therefore performed a comparative cost analysis of patients treated either within the Tumor Profiler (TuPro) melanoma project or from a control cohort who received treatment after standard next-generation sequencing testing. After adjustment of cohorts through inverse probability of treatment weighting, we found no evidence of statistically significant differences in total costs between the two cohorts (95% confidence interval -10% to +67%). Importantly, treatment costs (95% confidence interval -28% to +41%) were similar between the two cohorts. In conclusion, we found no evidence that treatment recommendations guided by advanced multi-omics profiling led to significantly higher treatment costs in a Swiss context.